Corbus Pharma tumbles on pricing $75 mln stock offering

Corbus Pharmaceuticals Holdings

31/10/2025 10:39

** Shares of Corbus Pharmaceuticals CRBP.O down 14.8% premarket at $14 after follow-on priced

    ** Norwood, Massachusetts-based oncology and obesity firm early Fri sold ~5.8 mln shares, including ~1 mln p
    re-funded warrants, for $75 mln gross proceeds

    ** Offering price of $13 is 20.9% discount to stock's last close

** It intends to use net offering proceeds to fund clinical development of its pipeline and for working capital and other purposes

** Jefferies acting as the bookrunner, per the statement. In the offering prospectus, Jefferies and Piper Sandler were cited as joint bookrunners

** CRBP has ~12.26 mln shares outstanding for about $200 mln market cap

** Through Thurs close, CRBP shares had gained ~77% over the past three months, putting them up 39% YTD

** Earlier this month, co shared early-stage data of CRB-701, its experimental therapy for head and neck cancer that has returned or spread after earlier treatments, at the annual European Society for Medical Oncology

** All 10 analysts covering CRBP are bullish and their median PT is $40, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))